Giraffe
Member
- Joined
- Jun 20, 2015
- Messages
- 3,730
Vaccination illusion: Measles vaccination and the surpressed facts - Interview with Dr. med. Suzanne Humphries | #Vaccination-en | Kla.TV
Safety of Live Attenuated Influenza Vaccine (LAIV)
I wonder if the SARS-CoV-2 vaccine will cause any kind of spreading. I'd prefer not to get 'passively immunized' as the WHO might put it (see 'vaccine derived polio').
Any thoughts?
Suzanne Humpries said:12:18 [...] when it comes to people with cancer... If you go into any cancer centre, there will be a sign on the wall that says "If you were vaccinated recently with a live virus vaccine, do not enter." We have a situation where live viral vaccines are actually shed from people who have been vaccinated. So they are a threat for the first few weeks after they're vaccinated. And there are several of those vaccines.
Safety of Live Attenuated Influenza Vaccine (LAIV)
CDC said:Shedding, Transmission, and Phenotypic Stability of LAIV Viruses
Shedding of the live attenuated vaccine virus is common after receipt of LAIV. In general, shedding is more common among younger recipients, among whom it may also be of longer duration. Among 345 LAIV3 recipients aged 5–49 years for whom shedding was assessed by viral culture of nasal swabs, 29% had detectable virus in nasal secretions. Prevalence of shedding was inversely related to age, and maximal shedding occurred within 2 days of vaccination. The symptoms most frequently reported after vaccination (runny nose, headache, and sore throat) did not correlate with the presence of shedding (522). In a study of 200 children aged 6 through 59 months, shedding of at least one vaccine virus was detected in 79% of children overall, and was more common among younger children (89% of 6- through 23-month-olds as compared with 69% of 24- through 59-month-olds) (523). Shedding had stopped in most cases by 11 days post vaccination. Vaccine virus was detected from nasal secretions in one (2%) of 57 HIV-infected adults who received LAIV3 compared with none of 54 HIV-negative participants (524), and in three (13%) of 24 HIV-infected children compared with seven (28%) of 25 children who were not HIV-infected (525).
Transmission of shed LAIV vaccine viruses from vaccine recipients to unvaccinated persons has been documented, but has not been reported to be associated with serious illness. One study of 197 children aged 9–36 months (98 of whom received LAIV3 and 99 of whom received placebo) in a child care center assessed the potential for transmission of LAIV3 vaccine viruses. Among vaccine recipients, 80% shed one or more vaccine virus (mean duration: 7.6 days). One influenza B vaccine virus strain isolate was recovered from a placebo recipient, and was confirmed to be vaccine-type virus. This transmitted virus isolate retained the cold-adapted, temperature-sensitive, attenuated characteristics. The placebo recipient from whom the influenza B vaccine virus strain was isolated had symptoms of a mild upper respiratory illness. The estimated probability of transmission of vaccine virus within a contact group with a single LAIV recipient in this population was 0.58% (95%CI = 0, 1.7) (526).
In a study of genotypic and phenotypic stability of LAIV vaccine viruses, nasal and throat swab specimens were collected from 17 study participants for 2 weeks after vaccine receipt. Virus isolates were analyzed by multiple genetic techniques. All isolates retained the cold-adapted and temperature-sensitive phenotypes (527). In a separate experimental study, serial passage of the LAIV H1N1pdm09 monovalent vaccine virus in Madin-Darby canine kidney (MDCK) cells at increasing temperatures resulted in a variant that reproduced at higher temperatures and produced severe disease in mice (528).
I wonder if the SARS-CoV-2 vaccine will cause any kind of spreading. I'd prefer not to get 'passively immunized' as the WHO might put it (see 'vaccine derived polio').
Any thoughts?
Last edited: